Compare the incidence of major cardiac adverse events (MACE) between both treatments
9% vs 41%, Odds Ratio .1, 95% C.I. 0.03-0.6, p=.006
MACE
Clinical signs of hypoperfusion
Signs of Heart Failure
Severe Hypotension (≤70mmHg SBP if pre-treatment BP ≤100mmHg and ≤80mmHg if pre-treatment BP >100mmHg)
Tachycardia acceleration > 20bpm
Fast Polymorphic VT
Patients with MACE usually required cardioversion
9% vs 41%, Odds Ratio .1, 95% C.I. 0.03-0.6, p=.006
MACE
Clinical signs of hypoperfusion
Signs of Heart Failure
Severe Hypotension (≤70mmHg SBP if pre-treatment BP ≤100mmHg and ≤80mmHg if pre-treatment BP >100mmHg)
Tachycardia acceleration > 20bpm
Fast Polymorphic VT
Patients with MACE usually required cardioversion
Clinical signs of hypoperfusion
Signs of Heart Failure
Severe Hypotension (≤70mmHg SBP if pre-treatment BP ≤100mmHg and ≤80mmHg if pre-treatment BP >100mmHg)
Tachycardia acceleration > 20bpm
Fast Polymorphic VT
compare the efficacy of both drugs in relation to the termination of tachycardia
67% vs. 38% (OR 3.3, 95% C.I. 1.2-9.3, p=0.026)
compare the incidence of adverse events (other than MACE)
24% vs. 48% (OR 0.34, 95% C.I. 0.12-1, p=0.052)
no significant difference
67% vs. 38% (OR 3.3, 95% C.I. 1.2-9.3, p=0.026)
24% vs. 48% (OR 0.34, 95% C.I. 0.12-1, p=0.052)
no significant difference
no significant difference
Patients with structural heart disease
lower MACE and higher termination rate in procainamide group
lower MACE and higher termination rate in procainamide group
PROCAMIO Trial
PART trial
FALLS protocol
ACS - Risk Stratification
STOPP/START criteria
Unstable Angina - NSTEMI Guidelines
Denver screening criteria
Recommendation Grading System